Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-A00228-35 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification in June 2021of previous recommendations concerning the postponing scheduled surgery suggesting local adaptations of this delay if epidemic developments appear. Today, the evolutions of the pandemic make these recommendations obsolete and impose the updating of the data produced during the first epidemic wave of 2020. Among these evolutions, the two most important are the existence of a large vaccination coverage on the one hand and the emergence of variants of lesser severity on the other hand
Previous studies performed during the first COVID-19 epidemic wave in the first half of 2020 led to the recommendation, after taking into account the individual risk-benefit balance, of postponing scheduled surgery for ideally at least 6 completed weeks in a patient with a positive preoperative SARS-CoV-2 PCR.
The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification of these recommendations in June 2021 suggesting local adaptations of this delay if epidemic developments appear. Today, the evolutions of the pandemic make these recommendations obsolete and impose the updating of the data produced during the first epidemic wave of 2020. Among these evolutions, the two most important are the existence of a large vaccination coverage on the one hand and the emergence of variants of lesser severity on the other hand
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with a positive preoperative SARS-CoV-2 test | Patient with a positive preoperative SARS-CoV-2 test |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Postponing surgery | Other | Postponing surgery for patients with Sars-cov-2 infection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Composite endpoint, that consist of respiratory morbidity associated with occurrence of respiratory events and use or prolongation of mechanical ventilation. | The primary endpoint will be a composite endpoint, that consist of respiratory morbidity associated with occurrence of pneumonia (bacterial or viral), acute respiratory distress, symptomatic pulmonary embolism (i.e. having led to a diagnostic procedure and a treatment), and postoperative prolongation of mechanical ventilation or the use of unscheduled, during the postoperative hospital stay and within the limit of 30 postoperative days. | up to 30 postoperative days. |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary Outcome Measures include hospital mortality, | The secondary endpoints will be the hospital mortality (number of death during hospitalization) | up to 30 postoperative days. |
| Secondary Outcome Measures include mortality at D30, |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient going to have surgery
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marc GARNIER, MD | HOPITAL TENON - PARIS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU d'Amiens | Amiens | France | ||||
| CHU d'Angers |
Not provided
Not provided
Not provided
Not provided
The secondary endpoints will be the mortality at D30 (number of death since surgery until Day 30);
| up to 30 postoperative days. |
| Secondary Outcome Measures include the occurrence of a deep vein thrombosis, | The secondary endpoints will be the number of occurrence of a deep vein thrombosis (excluding pulmonary embolism), | up to 30 postoperative days. |
| Secondary Outcome Measures include non-respiratory infection and septic shock, | The secondary endpoints will be the numberof non-respiratory infection or septic shock during the post-operative hospital stay and within the limit of postoperative 30 days. | up to 30 postoperative days. |
| Secondary Outcome Measures include non-respiratory infection or septic shock, | The secondary endpoints will be the number of non-respiratory infection or septic shock during the post-operative hospital stay and within the limit of postoperative 30 days. | up to 30 postoperative days. |
| Secondary Outcome Measures include length of hospital stay and length of critical care stay. | The secondary endpoints will be the length of hospital stay, length of critical care stay (if hospitalization in critical care). | up to 30 postoperative days. |
| Secondary Outcome Measures include the need for re-hospitalization during the first 30 days after surgery | The secondary endpoints will be the need for re-hospitalization during the first 30 days after surgery (number of patients with re-hospitalization) | up to 30 postoperative days. |
| Angers |
| France |
| CH Victor Dupouy | Argenteuil | France |
| Cinique Belharra | Bayonne | France |
| CH de Blois | Blois | France |
| CHU de Brest - la Cavale Blanche | Brest | France |
| HIA Clermont Tonnerre | Brest | France |
| CHU de Caen - Anesthésie Réanimation | Caen | France |
| CHU de Caen | Caen | France |
| CH Charleville Mézière - CH Intercommunal Nord Ardennes | Charleville-Mézières | France |
| AP-HP - Hôpital Beaujon | Clamart | France |
| Hôpital Antoine Béclère, Clamart | Clamart | France |
| CHU Clermont-Ferrand | Clermont-Ferrand | France |
| Centre Hospitalier Sud Francilien | Corbeil-Essonnes | France |
| CHU Grenoble-Alpes | La Tronche | France |
| CHU de Lille - hôpital Claude Huriez | Lille | France |
| Hôpital E. Herriot - Hospices Civils de Lyon | Lyon | France |
| CHU La Timone - Marseille | Marseille | France |
| Hôpital Nord, Marseille | Marseille | France |
| Clinique du Sport de Bordeaux Mérignac | Mérignac | France |
| CHU de Nantes | Nantes | France |
| Hopital Tenon | Paris | 75020 | France |
| AP-H P - Hôpital Lariboisière | Paris | France |
| AP-HP - Groupe Hospitalier Pitié-Salpêtrière (bloc central) | Paris | France |
| AP-HP - Groupe Hospitalier Pitié-Salpêtrière | Paris | France |
| AP-HP - Hôpital Bichat | Paris | France |
| AP-HP - Hôpital Saint-Antoine | Paris | France |
| AP-HP - Hôpital Saint-Louis | Paris | France |
| Clinique Drouot Rémusa | Paris | France |
| Clinique Saint Jean de Dieu | Paris | France |
| Centre Henri Becquerel | Rouen | France |
| CHU Sud Réunion (Saint-Pierre) | Saint-Pierre | France |
| CHU Strasbourg- Hautepierre | Strasbourg | France |
| CHU de Toulouse -Hôpital Purpan | Toulouse | France |
| CHU de Toulouse -Hôpital rangueil | Toulouse | France |
| Clinique Pasteur, Toulouse | Toulouse | France |
| CHRU de Tours - Hôpital Trousseau | Tours | France |
| Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy | France |
| Centre Gustave Roussy | Villejuif | France |
| Polyclinique de Villeneuve Saint Georges | Villeneuve-Saint-Georges | France |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided